34 results about "Tumor patient" patented technology

A method for treating cancer or a tumor, in particular treating cancer by combining two drugs, relating to the field of cancer treatment. A method for treating cancer by combining a drug containing an AKR1C3 enzyme-activated compound and an immune checkpoint inhibitor / immune cell treatment drug. In particular, the immune checkpoint inhibitor is selected from an anti-PD -1 antibody, an anti-PD-L1 antibody, an anti-CTLA-4 antibody, etc., and the AKR1C3 enzyme-activated compound is selected from the compound of the following structure (I).

This invention discloses an intelligent health education method, device, equipment, and storage medium for gynecological tumor patients. The method acquires the patient's electronic medical record information and patient interaction data. Based on the electronic medical record information, it identifies the gynecological tumor disease type and treatment stage tags. Based on the patient interaction data, it specifically identifies psychological stress signals related to gynecological tumor treatment, generating a profile of the patient's current psychosomatic state. It matches and dynamically generates personalized health education content and psychological counseling plans from a structured knowledge base. Based on the patient's treatment data, it automatically generates reminders for medication and follow-up examinations. It structurally correlates the output records of personalized health education content and the patient's feedback data on the reminders to form a digital pathmap for patient education. This enables dynamic matching and personalized generation of health education content and psychological counseling plans, improving the patient's cognitive adaptability to health information and the effectiveness of psychological support, achieving closed-loop management throughout the entire hospital and inpatient cycle.

The present invention provides an antitumor agent for treating a malignant tumor patient expressing EGFR having at least one mutation selected from the group consisting of L718X mutation in exon 18 and L792X mutation in exon 20, wherein X represents an arbitrary amino-acid residue, the antitumor agent comprising(S)—N-(4-amino-6-methyl-5-(quinolin-3-yl)-8.9-dihydropyrimido[5.4-b]indolizin-8-yl)acrylamide (Compound (A)) or a salt thereof.

This invention discloses an intelligent nutrition recommendation method for cancer patients based on metabolic rhythm synchronization, belonging to the field of nutrition recommendation. This invention integrates temporal physiological data and clinical information, extracts features, and uses a bidirectional long short-term memory network to predict the host metabolic activity curve. Based on a tumor knowledge graph, a conditional generative adversarial network is constructed to infer and generate a tumor metabolic activity curve using the host curve, tumor type, and treatment stage as conditions. A temporal separation potential heatmap is generated by calculating the phase difference and overlap between the two curves. Using the heatmap and clinical labels as states, an integrated constraint proximal strategy optimization algorithm is used for decision-making, outputting a time-segmented nutrient delivery action sequence that satisfies temporal nutritional constraints. Using this sequence as the target, an optimization algorithm performs a multi-objective search on a recipe database to generate a personalized daily recipe that considers both nutritional and taste preferences, providing cancer patients with timely and intelligent decision-making.

The application discloses damaged mitochondria as a malignant tumor metastasis prediction marker, and an application and detection system thereof, and is used for solving the problems of lacking specific prediction indexes and efficient and feasible prediction means for predicting malignant tumor metastasis in the prior art. The application rapidly enriches mitochondria from a to-be-detected plasma sample, detects the concentration of the prediction marker damaged mitochondria, and predicts the malignant tumor metastasis risk of a patient corresponding to the to-be-detected plasma sample based on the concentration of the prediction marker damaged mitochondria, so that whether the tumor patient will have metastasis in the future can be simply, rapidly and accurately predicted.

The present application relates to the technical field of biological medicines, and particularly relates to a polypeptide for specifically blocking the interaction between PD-L1 and endogenous double-stranded RNA and a medicine. The present application provides a polypeptide for specifically binding to endogenous double-stranded RNA, which has a strong effect on the activation of innate immune genes. The polypeptide fused with a cell-penetrating peptide can competitively bind to endogenous double-stranded RNA in cells and inhibit the A-to-I editing of endogenous double-stranded RNA, thereby improving the sensitivity of tumor cells to drugs. The present application provides a new strategy for the immunotherapy of tumor patients and has a wide application prospect.

The application relates to a compound traditional Chinese medicine composition for treating dermatitis of tumor patients, which is prepared from the following raw materials in parts by weight: 20-40 parts by weight of Huangqi, 5-15 parts by weight of Wumei, 5-15 parts by weight of Baishao, 5-15 parts by weight of Dilong and 10-20 parts by weight of Danshen, and a preparation method thereof is disclosed. The application can obviously improve the clinical dermatitis score related to skin lesions, reduce the spleen coefficient index, and also has the functions of reducing the epidermal thickness and inflammatory infiltration such as mast cells in the dermis, and reducing the inflammatory factor level in the skin lesions, which shows that the application can treat dermatitis of tumor patients.

The application relates to the technical field of artificial intelligence, and discloses a tumor patient prognosis risk stratification evaluation method and system based on deep learning and multi-omics data. The method comprises the following steps: collecting and pre-processing multi-omics data; extracting each omics specificity representation vector through a multi-path parallel network; generating a global prognosis atlas by fusing features by using a cross-modal attention mechanism; inputting a survival risk prediction model to output a risk score and a survival curve; and realizing risk stratification according to a threshold. The system comprises a data acquisition and preprocessing module, a feature mapping subsystem, a cross-modal fusion engine and a risk stratification calculation terminal. The application significantly improves the accuracy, robustness and interpretability of prognosis evaluation by deeply fusing multi-omics information and a deep learning architecture, and provides a scientific basis for clinical precise treatment.

This invention relates to the field of medical data processing technology, and in particular to a method and apparatus for predicting the survival of cancer patients. The method includes: acquiring molecular pathological examination results, histopathological examination results, and radiological imaging results of a target cancer patient; extracting features from the molecular pathological examination results, histopathological examination results, and radiological imaging results to obtain gene features, pathological image features, and MRI image features; fusing and stitching the gene features, pathological image features, and MRI image features to obtain a final fused feature; and predicting the actual survival range of the target cancer patient based on the final fused feature. This solves the problems of existing cancer survival prediction methods that often rely on single-modal information such as pathological images or radiological images, resulting in limited predictive performance and generalization ability, and making it difficult to provide sufficient and comprehensive reference for doctors and patients.

The use of AKR1C3 enzyme-activated DNA alkylating agent prodrug compounds containing aziridine structures, as well as their salts, esters, solvates, and isotopic isomers, in combination with anti-allergy drugs / nonsteroidal analgesics for the treatment of cancer and tumor patients; and the use of AKR1C3 enzyme-activated DNA alkylating agent prodrug compounds containing aziridine structures, as well as their salts, esters, solvates, and isotopic isomers, in combination with anti-allergy drugs / nonsteroidal analgesics in the preparation of drugs for the treatment of cancer and tumors.

The application provides a lung adenocarcinoma prognosis marker and model, a lung adenocarcinoma prognosis model based on programmed cell death (PCD) related mRNA and lncRNA is constructed, and the biological function of the lncRNA model in lung adenocarcinoma is explored through bioinformatics analysis and experiments. The prognosis model covers all PCD pathways and various molecules, has a robust prognosis prediction accuracy, and can provide potential molecular targets for personalized treatment. The method of the application comprehensively constructs a lung adenocarcinoma diagnosis model suitable for Chinese population by using PCD related mRNA and lncRNA, enhances the recognition ability of tumor patient classification from multiple aspects, improves the accuracy and reliability of prognosis prediction, can provide strong support for promoting the personalized treatment strategy of lung adenocarcinoma patients, and is suitable for popularization and application.

This invention provides a wound healing dressing for postoperative care of tumor patients and its preparation method, belonging to the field of postoperative dressing technology. The dressing comprises boric acid-grafted GelMA, caffeoyl tartaric acid-grafted CSMA, aldehyde-modified diallyl tartaramide, sodium alginate, catechins, ferric chloride, and calcium chloride. Its preparation process utilizes dynamic imine bonds, UV-induced covalent cross-linking, ionic cross-linking, and metal coordination to construct a multi-layered cross-linked interpenetrating network structure. The resulting dressing possesses both high strength and good toughness, allowing it to closely adhere to irregular wound surfaces. The rapid initial release of catechins provides immediate antioxidant and hemostatic effects, while catechols are continuously and slowly released under the influence of the microenvironment. Simultaneously, cationic chitosan, catechins, and iron ions synergistically provide antibacterial effects, and calcium alginate promotes coagulation, while GelMA promotes cell adhesion and proliferation, comprehensively promoting wound healing, reducing the risk of infection, and making it suitable for the care of complex wounds after tumor surgery.

The present application relates to the field of medicine, and particularly relates to application of sirolimus combined with immune checkpoint inhibitors in anti-tumor treatment. The present application discloses use of a combination of sirolimus or a derivative thereof and an immune checkpoint inhibitor in preparation of a medicament for treating tumors, a pharmaceutical composition and a kit comprising the combination, and a method for treating tumors by administering a therapeutically effective amount of the pharmaceutical composition or the kit to a tumor patient in need. The combination of the present application has a synergistic effect and is suitable for treating cancer.

The application discloses a kind of 18 The application discloses a risk prediction method for myocardial physiological uptake of F-FDG PET / CT tumor imaging, candidate clinical data of malignant tumor patients who have undergone examination are collected, independent risk factors for myocardial physiological uptake are determined by using single factor and multi-factor logistic regression analysis, and a logistic regression prediction model and multiple machine learning prediction models are established. The ROC curve analysis is used to select the pending prediction model with the largest AUC value. Furthermore, the application evaluates whether the pending prediction model is the best prediction model through calibration curve analysis and decision curve analysis. The best prediction model can be used to predict whether a new patient has the risk of myocardial physiological uptake before the examination, which has the advantages of fast prediction speed, high accuracy and reliability.

This invention relates to the field of medical and health information technology and discloses a home-based pain monitoring system for malignant tumor patients. The invention collects various data related to home care of malignant tumor patients, forming pain datasets, medication datasets, and vital sign datasets. Based on these three datasets, pain risk indices, medication risk indices, and vital sign risk indices are obtained. These are then weighted and summed to obtain a comprehensive risk index. Effective correlation and collaborative analysis of multi-dimensional data improve the accuracy of the comprehensive risk index. The system determines whether to issue an alert based on the comprehensive risk index. If the comprehensive risk index reaches a threshold, three different levels of alerts (red, orange, and yellow) are issued and sent to both the patient-side interaction module and the medical staff-side interaction module. Upon receiving the alert, medical staff immediately review the patient's current condition report, analyze it, and receive timely improvement suggestions to help the patient improve their current condition, thus improving the efficiency of home care.

The application relates to the technical field of medical information processing, and discloses a tumor prognosis model training method and system based on transdifferentiation related genes, which comprises the following steps: step 1, acquiring gene expression, clinical characteristics and survival follow-up data, and extracting transdifferentiation gene expression data; step 2, determining transdifferentiation gene normalization relative order values; step 3, determining a starting plasticity end index, a blood vessel acquisition end index and a transdifferentiation direction index; step 4, determining a microenvironment consequence index, coupling strength and a synergistic enhancement item; step 5, performing consistency screening to obtain a stable transdifferentiation characteristic gene set; step 6, performing constraint training to obtain a prognosis model weight parameter and a trained tumor prognosis model; and step 7, calculating a final prognosis risk score, determining an optimal risk classification threshold, and obtaining a risk stratification result. The application realizes the generation of a tumor patient prognosis risk score and a risk stratification result.

The present invention relates to a use of a biomarker in the metastasis risk diagnosis and treatment of a tumor lymph node, and specifically relates to a use of specific recognition of a biomarker SPP1+TAM in combination with an existing N0-N3 lymph node metastasis classification system in the clinical metastasis risk diagnosis and treatment of a tumor lymph node. By means of systematical analysis on metastatic lymph nodes and non-metastatic lymph nodes of a variety of tumor patients, it is discovered that SPP1+TAM is associated with a N0-N3 staging system for lymph node metastasis in the tumor lymph node metastasis risk diagnosis. Provided is a clinical application of SPP1+TAM in combination with an N0-N3 staging system in the assisted or alternative metastasis risk diagnosis and guided treatment of a tumor lymph node. Also provided is a corresponding kit for the tumor lymph node metastasis risk diagnosis.

This invention discloses the E3 ubiquitin ligase ASB7 as a molecular marker for predicting PARP inhibitor therapy sensitivity and its application. Through cell biology experiments and animal model studies, this invention found that tumor cells and tissues with high ASB7 expression exhibit significant sensitivity to PARP inhibitors. Specifically, ASB7 induces homologous recombination repair (HRR) deficiency, increasing genomic instability and thus enhancing the sensitivity of tumor cells to PARP inhibitors. This ASB7 molecular marker provides new insights for precision medicine, offers an optimized treatment strategy for tumor patients with high ASB7 expression, and lays a solid foundation for the development of highly effective anti-tumor drugs, demonstrating significant application prospects and clinical significance.

The application discloses application of a combination marker in survival time of tumor patients and treatment effect prediction of an immune checkpoint inhibitor, and proposes an ISG15 + macrophages and SPP1 + The macrophage infiltration level is used as the combination marker, the ratio of the two is used as a kit for the survival time of tumor patients and the treatment effect of the immune checkpoint inhibitor, the survival time of tumor objects and the treatment effect of the tumor immune checkpoint inhibitor can be effectively predicted, patients sensitive to the immune checkpoint inhibitor treatment can be effectively screened, the response rate of the tumor immune checkpoint inhibitor treatment is improved, and the combination marker has good clinical transformation and application prospect.

The objective is to identify biomarkers that can monitor the disease state of tumors and to provide methods for determining the effectiveness of tumor treatment, monitoring recurrence, assessing the risk of recurrence, predicting prognosis, or assisting in diagnosis. [Solution] Focusing on the methylation status of ctDNA as a regulatory mechanism for epigenetic gene modification in tumor development, we found that certain genes are highly methylated in tumor tissue from tumor patients compared to non-tumor tissue, and that changes in the methylation level of these genes in ctDNA correlate with the disease state of the tumor. Therefore, we discovered that this can be used as a biomarker to monitor the disease state of tumors.

The application discloses a traditional Chinese medicine composition for assisting tumor patients in warming yang, removing blood stasis and relieving pain and a hot compress bag thereof, and relates to the technical field of externally used hot compress traditional Chinese medicine.The traditional Chinese medicine composition comprises the following raw materials: prepared aconite, dried ginger, evodia, Sichuan pepper, cumin, astragalus, angelica, cassia, fried raphanus and fried licorice.This traditional Chinese medicine composition takes the thought of supporting yang as the core, follows the prescription logic of'supporting yang to consolidate the foundation and removing evil without damaging the healthy qi', precisely matches the physical characteristics of tumor patients 'deficiency of healthy qi as the root and evil toxin and blood stasis as the branch', and through the compatibility of medicinal materials for warming and supporting the congenital kidney yang, warming and dredging the meridian blood stasis and tonifying qi and nourishing blood to support the healthy qi, the core pathogenesis of 'yang deficiency-cold coagulation-toxin and blood stasis' of cancer patients is directly attacked, the yang deficiency constitution is regulated, the double goals of symptom relief and constitution improvement are realized, the pathological vicious circle is prevented, the regulation is more fundamental, and the limitation of only relieving the superficial symptoms without treating the root is avoided.

The utility model relates to the technical field of medical auxiliary equipment, concretely provides a kind of ICU nursing auxiliary equipment of tumor patient, wherein, including nursing bed body, nursing bed bottom plate and compression spring;The side wall of nursing bed body is connected with extension plate body by electric slide rail, the side wall of extension plate body is fixedly connected with magnetic attraction plate, and auxiliary instrument is arranged by magnetic attraction force, the side wall of nursing bed body is equipped with accommodating cavity, and the inside fixed connection of accommodating cavity has connecting crosspiece, the top of connecting crosspiece is slidably connected with sliding part, the side wall of sliding part is fixedly connected with reinforcing belt body, and reinforcing belt body is made of elastic material, the compression spring can be wound on extension plate body and auxiliary instrument, and compression spring is used to limit the position between extension plate body and auxiliary instrument.The utility model effectively solves the problem that multiple different instruments cannot be limited in the prior art, achieves the purpose of improving overall use stability and safety.

The application provides a computer-implemented method and device for tumor treatment strategy prediction, and belongs to the technical field of biological medicine. The method comprises the following steps: obtaining the proportion of target antigen-positive immune cells in total immune cells in a target sample; based on the difference between the proportion and a predetermined threshold, dividing the antigen expression level of the target sample to obtain a grouping result; wherein the grouping result is any one of N preset level groupings, and N is an integer not less than 1; based on the grouping result, matching a corresponding treatment strategy, wherein the treatment strategy comprises: administering an effective dose of an antibody corresponding to the target antigen and / or an immune checkpoint inhibitor antibody. By constructing a multi-level hierarchical mechanism based on the expression proportion of immune-related antigens and establishing a mapping relationship between the hierarchical result and the treatment strategy, fine immunotyping of tumor patients and individualized treatment strategy prediction are realized, so that the accuracy, safety and medical resource utilization rate of immunotherapy are improved.

The present application provides the application, method and drug related to the regulation of tumor or inflammatory disease related macrophage infiltration by CREPT. The present application also provides the application of the inhibition of CREPT positive tumor associated macrophage (TAM) in the preparation of the preparation for regulating the tumor microenvironment, and the application in the preparation of the drug for treating tumor or promoting the action of T lymphocyte. The inhibition of the CREPT positive tumor associated macrophage (TAM) can provide a technical means for controlling tumor proliferation, invasion and metastasis. The CREPT positive tumor associated macrophage (TAM) can also be used as a biomarker for the risk of an individual suffering from tumor, or a biomarker for the development stage of the tumor of an individual, to judge the risk of an individual suffering from tumor or the stage and progress of the tumor of a tumor patient.

The present application relates to the technical field of intelligent medical prediction, in particular to a kind of intelligent early warning method and system for adverse reactions of tumor patient chemotherapy drug, method includes: the gene sequencing data of current patient, time sequence physiological index data are input to network model, network model output damage stage;The training data set of network model includes: gene sequencing data, time sequence physiological index data and damage stage;The acquisition process of damage stage includes: based on gene sequencing data, the relative metabolic rate thereof to chemotherapy drug is acquired, and then the relative speed of its in-vivo toxicity accumulation is determined;After the time sequence physiological index data of meaningless physiological fluctuation of historical patient is smoothed, the nerve damage change curve is acquired according to time sequence physiological index data, and then whether there is potential subclinical signal segment in it is identified, if yes, then it is judged damage stage according to this.The present application can realize individualized, accurate risk prediction before irreversible nerve damage occurs caused by chemotherapy.

The embodiment provides a tumor-targeting drug medication efficacy evaluation device and method, the device comprises a PEC sensing electrode, an excitation light source and a data processing circuit, the irradiation range of the excitation light source covers the PEC sensing electrode; the PEC sensing electrode is electrically connected with the data processing circuit; the PEC sensing electrode is used to be placed in a buffer electrolyte, the buffer electrolyte is an acidic buffer electrolyte, and the buffer electrolyte is used to acidify a blood sample of a tumor patient; under the irradiation of the excitation light source, the PEC sensing electrode is used to transmit a detection electric signal to the data processing circuit, the detection electric signal is used to indicate the iron ion content in the blood sample of the tumor patient, the tumor-targeting drug is a targeting drug based on a cell iron death mechanism, and the iron ion content in the blood sample of the tumor patient is used to evaluate the medication efficacy of the tumor-targeting drug on the tumor patient. The embodiment of the application can simply, timely, efficiently and accurately realize the detection of the iron content in the patient's body to evaluate the medication efficacy of the targeting drug of the patient.